Question 1

What does Celldex Therapeutics do in rare disease treatment?

Accepted Answer

Celldex Therapeutics is a biopharmaceutical company developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other rare diseases. The company's lead program barzolvolimab (CDX-0159) is a monoclonal antibody for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis.

On September 22, 2026, Celldex reported that both Phase 3 EMBARQ-CSU trials in chronic spontaneous urticaria met their primary endpoint (change in UAS7 at week 12) and all key secondary endpoints, with 42–46% of treated patients achieving complete response versus 9–13% on placebo. A BLA submission is planned for 2027.

Question 2

What rare diseases does Celldex Therapeutics focus on?

Accepted Answer

Celldex Therapeutics has active programs across 5 rare diseases: C3 Glomerulopathy, Cholangiocarcinoma, Eosinophilic Esophagitis, Hodgkin Lymphoma, Waldenström Macroglobulinemia. Each disease page on Trial Friend shows the latest recruiting trials, FDA-approved treatments, and patient resources.

Question 3

Does Celldex Therapeutics have a rare disease division?

Accepted Answer

Celldex Therapeutics is a diversified pharmaceutical company headquartered in Hampton, United States, founded in 1983. While it operates across multiple therapeutic areas, it maintains a significant rare disease portfolio with 5 active rare disease programs including C3 Glomerulopathy, Cholangiocarcinoma, Eosinophilic Esophagitis. Many of its rare disease treatments hold orphan drug designations from the FDA.

Question 4

How can I find Celldex Therapeutics clinical trials for rare diseases?

Accepted Answer

This page shows all active and recruiting clinical trials sponsored by Celldex Therapeutics, pulled live from ClinicalTrials.gov. Each trial card includes the study phase, recruitment status, conditions being studied, number of trial sites, and a direct link to the full study record. You can also explore individual disease pages to see trials from all sponsors for a specific condition.

Question 5

How do I enroll in a Celldex Therapeutics clinical trial?

Accepted Answer

To explore enrollment, find a recruiting trial on this page and click "View full study" to see the full ClinicalTrials.gov record, which includes eligibility criteria, study locations, and contact information for each trial site. Your doctor can also help determine if a specific trial is appropriate for your condition. Not all trials are open at every location, so check the site list for one near you.

Question 6

What FDA-approved rare disease drugs does Celldex Therapeutics have?

Accepted Answer

The FDA-Approved Drugs section on this page lists all Celldex Therapeutics drugs with FDA approval that are relevant to rare diseases, including brand names, generic names, approval dates, and the rare conditions each drug treats. This data comes from the FDA's openFDA database and is updated automatically.

Question 7

When was Celldex Therapeutics founded and where is it based?

Accepted Answer

Celldex Therapeutics was founded in 1983 and is headquartered in Hampton, United States. The company has been active for 43 years. It trades publicly under the ticker symbol CLDX.

Celldex Therapeutics

Active Clinical Trials

FDA-Approved Drugs

Rare Disease Focus Areas (5)

Patient Resources

Frequently Asked Questions About Celldex Therapeutics

Active Clinical Trials

FDA-Approved Drugs

Rare Disease Focus Areas (5)

Related Companies

Patient Resources

Frequently Asked Questions About Celldex Therapeutics